About Ischemix
Ischemix: Advancing Cytoprotective Therapies
Ischemix is a biotechnology company that is dedicated to advancing cytoprotective therapies. The company was founded in 2014 by a team of experienced scientists and entrepreneurs who recognized the need for new treatments that could protect cells from damage caused by ischemia, or lack of oxygen.
The Ischemix team has developed a unique approach to cytoprotection that involves targeting specific proteins and pathways within cells. By doing so, they are able to activate natural defense mechanisms that can help prevent cell death and promote tissue repair.
One of the key areas of focus for Ischemix is acute kidney injury (AKI), which occurs when the kidneys suddenly stop working properly. AKI can be caused by a variety of factors, including surgery, trauma, infections, and medications. It is a serious condition that can lead to long-term kidney damage or even death if not treated promptly.
Ischemix's lead product candidate is called ISX-1, which has shown promising results in preclinical studies as a potential treatment for AKI. ISX-1 works by activating the Nrf2 pathway within cells, which helps protect against oxidative stress and inflammation.
In addition to AKI, Ischemix is also exploring other potential applications for its cytoprotective therapies. These include ischemic stroke (a type of stroke caused by lack of blood flow to the brain), myocardial infarction (heart attack), and traumatic brain injury.
Ischemix's approach to cytoprotection has garnered attention from investors and industry experts alike. In 2019, the company raised $5 million in Series A funding led by Broadview Ventures and joined by New Enterprise Associates (NEA) as well as other investors.
The company's leadership team includes CEO Dr. Michael Bristow; Chief Scientific Officer Dr. Robert Kloner; Chief Medical Officer Dr. David Brown; and Chief Business Officer Dr. John Hulme.
Ischemix is headquartered in Irvine, California, and has a team of scientists and researchers working to advance its cytoprotective therapies. The company is committed to bringing new treatments to patients who need them most, and is poised to make a significant impact in the field of biotechnology.
In conclusion, Ischemix is a biotechnology company that is dedicated to advancing cytoprotective therapies for the treatment of acute kidney injury (AKI), ischemic stroke, myocardial infarction (heart attack), traumatic brain injury, and other conditions caused by lack of oxygen or blood flow. Its lead product candidate ISX-1 has shown promising results in preclinical studies as a potential treatment for AKI by activating the Nrf2 pathway within cells. With its experienced leadership team and innovative approach to cytoprotection, Ischemix is poised to make a significant impact in the field of biotechnology.